Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Exiqon announces the recognition of ICCB-L

Exiqon A/S announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence.

30 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

Dr. Sarit Larisch receives the prestigious Johnson & Johnson Focused Funding grant

Dr. Sarit Larisch, Head of the Cell Death Research Laboratory in the University of Haifa's Department of Biology, has been awarded the prestigious Johnson & Johnson Focused Funding grant for her research exploring the cause of brain cell damage in Parkinson's disease.

26 Nov 2009

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

‏Dr. Sarit Larisch, Head of the Cell Death Research Laboratory and senior lecturer at the University of Haifa, has been awarded the prestigious Johnson & Johnson Focused Funding grant for her research exploring the cause of brain cell damage in Parkinson's disease.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009.

25 Nov 2009

People with severe EBS at increased risk of skin cancer, say scientists

UK scientists have discovered the link between people with the skin blistering disease Epidermolysis Bullosa Simplex-Dowling-Meara, (EBS -DM) - and tumour growth, according to research published in Journal of Investigative Dermatology today (Monday).

25 Nov 2009

Innovation Award for GMI presented at the 2009 World Congress on Medical Physics

Gamma Medica-Ideas, Inc., a leading developer of digital molecular imaging systems, announced today that it has been awarded an Innovation Award for its new prototype imaging system that combines the molecular imaging (MI) capability of single-photon nuclear imaging with magnetic resonance imaging (MRI). The award was presented to GMI at the 2009 World Congress on Medical Physics and Biomedical Engineering in Munich, Germany that took place on September 7th, 2009.

24 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent.

18 Nov 2009

First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009.

17 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

New insights into cells' reaction to DNA damage

Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression.

17 Nov 2009

Apoptosis News and Research

Exiqon announces the recognition of ICCB-L

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Dr. Sarit Larisch receives the prestigious Johnson & Johnson Focused Funding grant

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

Human Genome Sciences submits BLA for ZALBIN

'Suicide gene E' reduces potent drug dosage in cancer patients

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

People with severe EBS at increased risk of skin cancer, say scientists

Innovation Award for GMI presented at the 2009 World Congress on Medical Physics

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Study: EP4 agonist may reduce gastric bleeding and inflammation

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Cancer-fighting protein successfully placed directly into solid tumors and turned on

First-quarter fiscal 2010 results announced by Senesco Technologies

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

New insights into cells' reaction to DNA damage

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News